Home/ Stocks/ IMNN

Imunon, Inc. Common Stock

IMNN XNAS

$2.94 -0.30 (-10.07%) ▼ 15-min delayed

Open

$2.94

High

$3.00

Low

$2.83

Volume

33.1K

Market Cap

$10.13M

About Imunon, Inc. Common Stock

Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).

Sector: PHARMACEUTICAL PREPARATIONS Employees: 25 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q3 2025	$0	$-3,429,124	$-1.16
Q2 2025	$0	$-2,740,559	$-2.15
Q1 2025	$0	$-4,102,495	$-0.28
FY 2024	$0	$-18,620,242	$-1.62

Related Market News

No specific coverage for IMNN yet. Check out our latest market news or earnings calendar.

Get IMNN Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Imunon, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.